Protagonist Therapeutics Inc’s filing revealed that its Chief Medical Officer MOLINA ARTURO MD unloaded Company’s shares for reported $1.16 million on Nov 27 ’24. In the deal valued at $44.70 per share,26,000 shares were sold. As a result of this transaction, MOLINA ARTURO MD now holds 46,444 shares worth roughly $1.93 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, MOLINA ARTURO MD sold 5,529 shares, generating $252,122 in total proceeds. Upon selling the shares at $45.60, the Chief Medical Officer now owns 46,444 shares.
Before that, Gupta Suneel sold 103,437 shares. Protagonist Therapeutics Inc shares valued at $4,762,239 were divested by the Chief Development Officer at a price of $46.04 per share. As a result of the transaction, Gupta Suneel now holds 256,174 shares, worth roughly $10.66 million.
Goldman initiated its Protagonist Therapeutics Inc [PTGX] rating to a Neutral in a research note published on December 06, 2024; the price target was $47. A number of analysts have revised their coverage, including BMO Capital Markets’s analysts, who began to cover the stock in early December with a ‘”an Outperform”‘ rating. Wedbush began covering PTGX with “an Outperform” recommendation on November 05, 2024. TD Cowen started covering the stock on September 24, 2024. It rated PTGX as “a Buy”.
Price Performance Review of PTGX
On Tuesday, Protagonist Therapeutics Inc [NASDAQ:PTGX] saw its stock jump 2.72% to $41.60. Over the last five days, the stock has gained 0.85%. Protagonist Therapeutics Inc shares have risen nearly 81.42% since the year began. Nevertheless, the stocks have risen 104.32% over the past one year. While a 52-week high of $48.89 was reached on 10/28/24, a 52-week low of $19.00 was recorded on 01/05/24. SMA at 50 days reached $44.60, while 200 days put it at $36.71.
Levels Of Support And Resistance For PTGX Stock
The 24-hour chart illustrates a support level at 40.63, which if violated will result in even more drops to 39.67. On the upside, there is a resistance level at 42.47. A further resistance level may holdings at 43.35. The Relative Strength Index (RSI) on the 14-day chart is 44.50, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.38, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 63.74%. Stochastics %K at 47.55% indicates the stock is a holding.
How much short interest is there in Protagonist Therapeutics Inc?
A steep rise in short interest was recorded in Protagonist Therapeutics Inc stocks on 2024-11-29, growing by 0.12 million shares to a total of 3.4 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-31 was 3.28 million shares. There was a rise of 3.46%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 09, 2024 when Truist began covering the stock and recommended ‘”a Buy”‘ rating along with a $60 price target.
